DailyIQ
|
DailyIQ
|
Sector:HealthcareAll sectors
Last updated3 minutes ago

ROIV·Roivant Sciences Ltd.

$36.62
+0.29 (+0.79%)
Overnight$36.91+0.29 (+0.79%)
High
$36.92
Open
$0.00
Market Cap
27.61B
52W High
$46.09
Low
$36.91
P. Close
$36.62
P/E
-
52W Low
$18.82
Fwd P/E
-26.43
DailyIQ Est.
$52.30
Inst. Own.
22.7%
Short Interest
5.39%
Days to Cover
7.9
NewEarnings release, scored · filed Aug 6, 2026tone -7.8 vs prior release · 56 lines scoredSee the breakdown
Technical Score (1D)
92
BULLISH
News Sentiment
59
BULLISH
On Nov 5, analysts noted that Roivant Sciences’ stock had risen sharply over the past five years, prompting questions about whether the current price aligns with the company’s book value. They highlighted that the firm’s business model, which focuses on developing and commercializing drug assets, raises concerns about future profitability and capital requirements that could affect its net asset base. Investors are evaluating whether the share price reflects realistic expectations of the company’s underlying assets. The analysis underscored that Roivant’s stock had surged 383.9% over five years, a fact that has fueled the debate. The discussion centers on whether the steep price increase is justified given the uncertainties surrounding the company’s ability to generate sustainable earnings and manage capital needs.
LOW TARGET
$41 +12.0%
2 analysts
MEAN TARGET
$50 +36.5%
6 analysts
HIGH TARGET
$62 +69.3%
14 analysts
PRICE RANGE
$41.00 - $62.00
SB / B / H / S / SS
9/8/3/1/1
DAILYIQ EST.
$52.30 (+42.8%)
Sector
Healthcare
Industry
Biotechnology
Exchange
NMS
Country
United Kingdom
Website
roivant.com
Symbol
ROIV
Description
Roivant Sciences is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative medicines and technologies. The company's pipeline features a diverse range of product candidates, including fully human monoclonal antibodies like IMVT-1402 and batoclimab, designed to address various autoimmune diseases such as Graves' disease and thyroid eye disease. Roivant also has a small molecule inhibitor, brepocitinib, in development for conditions like dermatomyositis and uveitis. A key focus for the company is mosliciguat, an inhaled activator targeting pulmonary hypertension. Furthermore, Roivant leverages delivery platforms, including lipid nanoparticle and ligand conjugate technologies, to enhance its drug development capabilities.
Bought (1Y)
0 shares
$0
Sold (1Y)
8,549,112 shares
$296.9M
Venker EricPresident & Immunovant CEO
Sell200,000 shares2026-11-03
Venker EricPresident & Immunovant CEO
Sell200,000 shares2026-10-28
MOMTAZEE JAMES C-
Tax Withholding77 shares2026-10-23
MOMTAZEE JAMES C-
Award/Grant383 shares2026-10-23
Epperly Melissa B,-
Tax Withholding116 shares2026-10-23
View full insider trading history →
29/ 100
Bearish
Overall: Bearish
✕Revenue declining year over year
✕Negative net margin
✕Negative operating cash flow
Net Margin
-3629.2%
Revenue CAGR
-19.1%
Current Ratio
18.37x
Debt / Equity
0.10x
Return on Equity
-6.6%
View full financials →
Earnings Summary
In Q1 2025 the company posted a revenue of $7.57 million, while EPS fell to –$0.218, missing the –$0.163 estimate; Q2 2025 revenue guidance of $4.11 million was not reported and EPS data is unavailable, but Q1 2026 revenue dropped to $1.999 million with EPS improving to –$0.240 versus the –$0.311 estimate, indicating a modest acceleration in earnings performance despite a sharp revenue decline. Historically, Roivant has struggled to achieve positive earnings, with negative EPS in each quarter examined, yet revenue has fluctuated widely, suggesting a focus on pipeline development over cash generation. Recent news highlights Phase 3 data for Brepocitinib in non‑infectious uveitis, with primary endpoints met and a regulatory filing anticipated in 2027; however, no financial guidance was provided, so the impact on earnings remains unclear.

EPS

EstBeatMiss
$-0.49$-0.40$-0.31$-0.21$-0.12Q1'25Q1'26Q2'25
QtrEstActual+/−
Q2'25$-0.45 - -
Q1'26$-0.31$-0.24+23.0%
Q1'25$-0.16$-0.22-33.6%

Revenue

EstBeatMiss
$1M$3M$5M$7M$8MQ1'25Q1'26Q2'25
QtrEstActual+/−
Q2'25$4M - -
Q1'26 - $2M -
Q1'25 - $8M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ROIV Stock Snapshot

BULLISH92/100
$36.91+$0.29 (0.8%)
Market cap
27.61B
Day range
$36.91 – $36.92
News sentiment
59/100 · Neutral
Analyst target
$50.00 (+35.5%)
Consensus
Strong Buy · 22 analysts
52-week range+96.1% off low · -19.9% from high
$18.82$46.09
Price $36.91 DailyIQ Est. $52.30

Roivant Sciences Ltd. screens well technically, with price sitting in the middle of its 52-week range. Earnings and guidance carry more weight than macro data at this capitalisation.

Behaviour On Record

What ROIV's own history says about today's numbers

Realized volatility (21d)
40.7% 43rd pct
Below its peak
-8.2%
vs 200-day average
+20.7%
Up days (1y)
50%

Roivant Sciences Ltd. is currently running 40.7% annualised volatility over the last 21 sessions. Measured against ROIV's own 6 years of daily returns rather than a market-wide average, that is the 43rd percentile — close to its own typical level, against a typical reading of 44.9%.

ROIV is trading -8.2% below its running peak. Across 6 full years on file, its median worst-drawdown-in-a-year was -30.0%, and the deepest was -71.6% in 2022. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +20.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 63rd percentile — a somewhat wider gap than its own norm. Over the past year ROIV closed higher on 50% of sessions, and it is currently 3 sessions into a rising streak.

On November specifically: over 5 years of records, ROIV finished the month higher 4 of 5 times, with a median return of +4.2% and an average of +1.4%. Its strongest month historically has been December at +10.0% on average, its weakest March at -8.7%.

Overnight risk is measurable too: ROIV has opened more than 2% away from the prior close in 292 of 1,484 sessions (19.7% of the time), with the largest gaps running +14.9% and -10.6%.

All figures computed from 1,485 daily closes between 2020-12-08 and 2026-11-05, split-adjusted, recomputed daily. Percentiles are against ROIV's own 6-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ROIV's sector?

Roivant Sciences Ltd. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, ROIV ranks 9th of 15 tracked industries, weakening.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
100
Industry rank
#9 of 15

Options Market

What is the options market pricing for ROIV?

CallsPuts

For Roivant Sciences Ltd.'s nearest expiry (2026-11-20, 14 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.26), with at-the-money implied volatility around 104.2%. The options market is pricing roughly a ±17.6% move by that expiry — a range of about $29.95–$42.75.

Put/call ratio (2026-11-20)
0.26
ATM implied volatility
104.2%
Total open interest
10,056
Expected move by 2026-11-20
±17.6% ($29.95–$42.75)

Analyst Consensus Estimates

What do analysts expect ROIV to earn?

Analysts expect Roivant Sciences Ltd. to earn -$1.56 per share in the fiscal year ending Mar 2027 and -$1.39 in the fiscal year ending Mar 2028, from 4 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Sep 2026-$0.45-$0.59 to -$0.353$4M11
Dec 2026-$0.40-$0.50 to -$0.353$14M11
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Mar 2027-$1.56-$1.89 to -$1.233$57M12
Mar 2028-$1.39-$1.93 to -$0.594$429M12

Analyst Rating Changes

Are analysts turning bullish or bearish on ROIV?

Citigroup most recently reiterated its rating on Roivant Sciences Ltd. to Buy on Oct 28, 2026 with a price target of $56 (from $46). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
Citigroup: Buy
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Oct 28, 2026CitigroupMaintainedBuy$46 → $56
Oct 12, 2026Wolfe ResearchDowngradeOutperform → Peer Perform-
Sep 17, 2026StifelInitiatedBuy$51
Sep 9, 2026TD CowenMaintainedBuy$50 → $55
Sep 9, 2026GuggenheimMaintainedBuy$42 → $46
Sep 8, 2026HC Wainwright & Co.MaintainedBuy$41 → $47
Sep 8, 2026JefferiesMaintainedBuy$42 → $52
Aug 28, 2026HC Wainwright & Co.ReiteratedBuy$41
Aug 10, 2026CitigroupMaintainedBuy$42 → $46
Aug 7, 2026GuggenheimMaintainedBuy$36 → $42
Aug 7, 2026HC Wainwright & Co.MaintainedBuy$34 → $41
May 26, 2026GuggenheimMaintainedBuy$30 → $36

Earnings Release, Scored

What did Roivant Sciences Ltd.'s latest earnings release say?

Filed Aug 6, 2026 · SEC Form 8-K, Exhibit 99

Tone56.1/ 100-7.8 vs prior release
Hedging words0.33per 100 words+0.06 vs prior release
Tone, last 2 releasesScale 50–70

Most important lines

  1. 1

    In Phase 2, 77% of brepocitinib 45mg patients achieved this endpoint compared to 0% of placebo patients.

    New this quarter
  2. 2

    On a per common share basis, net loss was $0.26 and $0.33, respectively, for the three months ended June 30, 2026 and 2025.

    Negative tone
  3. 3

    Non-GAAP net loss was $243.7 million for the three months ended June 30, 2026, compared to $170.1 million for the three months ended June 30, 2025.

    Negative tone

Scores describe the release's wording. They are not a forecast.

Read all 56 scored lines →

Peers & ETF holders

ROIV peers & ETF holders

BiotechnologyMarket cap · today

Top ETF holdersWeight

News & sentiment

What is the news saying about ROIV?

ROIV rose 1.8% over the month to Nov 5. News tone held between 22 and 100 from Oct 5 to Nov 3, then dropped to 33 on Nov 5.

Daily close and news tone, Oct 5 to Nov 5
$35$38Oct 5: tone 50Oct 6Oct 7Oct 8: tone 22Oct 9Oct 12: tone 49Oct 13Oct 14Oct 15Oct 16Oct 19: tone 57Oct 20Oct 21: tone 76Oct 22: tone 32Oct 23: tone 86Oct 26Oct 27Oct 28: tone 73Oct 29: tone 33Oct 30Nov 2: tone 37Nov 3: tone 100Nov 4Nov 5: tone 33Oct 5News toneNov 5123
  1. Oct 13 -4.1%
  2. Nov 4 +6.1%
  3. Nov 5 -4.2%same day: Roivant Sciences (ROIV) Stock Looks Expensive Against Its Book Value
Latest stories naming Roivant Sciences

Technical analysis

How strong is ROIV's momentum right now?

On the daily chart ROIV ranks at the 92nd percentile for momentum against 1,060 stocks and ETFs, a bullish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling ROIV?

78 of the 120 tracked managers added to ROIV in their latest 13F and 39 trimmed. Together they own 22.7% of the company, worth $6.0B. Vanguard Capital Management and Vanguard Portfolio Management alone hold 5.8%.

78adding39trimming3unchanged
Largest holders by stake, latest 13FBar = share of ROIV
  1. 1Vanguard Capital Management LLC2.96%
    $782.9M positionAdded 7.0% last quarter
  2. 2Vanguard Portfolio Management LLC2.89%
    $765.9M positionAdded 9.1% last quarter
  3. 3State Street Corp2.38%
    $629.8M positionAdded 9.9% last quarter
  4. 4UBS Group AG2.33%
    $618.1M positionTrimmed 22.8% last quarter
  5. 5Farallon Capital Management LLC1.91%
    $506.4M positionAdded 47.9% last quarter
  6. 6Dimensional Fund Advisors LP0.66%
    $181.2M positionTrimmed 5.2% last quarter
  7. 7Baker Bros. Advisors LP0.63%
    $166.9M positionTrimmed 3.1% last quarter
  8. 8Jennison Associates LLC0.60%
    $158.6M positionAdded 50.3% last quarter
  9. 9Pictet Asset Management Holding SA0.56%
    $152.6M positionAdded 20.3% last quarter
  10. 10Charles Schwab Investment Management Inc0.50%
    $131.5M positionAdded 7.5% last quarter
Full holdings history

Congressional trading

Is Congress trading ROIV?

1 member of Congress disclosed 3 ROIV trades between Oct 30 and Oct 31, 2025: 1 buy and 2 sells, about $24.0K in estimated value.

BuysSellsOct
BuySell$1K–$15K$15K–$50K$50K–$100K$100K–$250K

What stands out

Click one to highlight its trades in the chart
Full trading history

Discover more

How has ROIV done against its peers?

Over the six months to Nov 5, ROIV returned +29.4%. Of the 15 related stocks and ETFs, 4 did better, led by MRNA at +418.8%.

Change since May 5, through Nov 5
−200%0%+200%+400%+600%May 5JunJulAugSepOctNov 5MRNA +418.8%ROIV +29.4%ALNY −48.0%